Metagenomi (MGX) Short-Term Debt to Equity

Corporate emblem and logo of Metagenomi, Inc. (MGX)

The genetic correction sector is characterized by fierce competition and the risk of patent disputes with major players. This daily price action for Metagenomi, Inc. (MGX), whose metric stands at 0.02, illustrates the company's progress in developing DNA-based therapeutics. Growth is driven by AI-powered discovery of new editing systems and a substantial liquidity cushion. Current revenue is based on licensing payments from pharma behemoths while the first clinical trials are being prepared.

MGX - Metagenomi Therapeutics Current Liabilities to Capital over the range 02/21/2024 - 11/01/2026

Analytical breakdowns for Metagenomi, Inc.

- stock quotes and analyst forecast:
Stock Price Metagenomi, Inc|MGX - Analyst Consensus Forecast
- market capitalization details:
Market Value Metagenomi Inc.|MGX - Real Price to Acquire Entire Company
- balance sheet equity data:
Book Value per Share Metagenomi|MGX - Total Stockholders' Equity|Market Cap to Net Assets Ratio metagenomi.co|MGX - Aggregate Business Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Metagenomi, Inc.|MGX - Long-Term Debt to Capital|Short-Term Debt to Capital Metagenomi|MGX - Company Total Indebtedness|Debts to Book Capitalization Metagenomi Inc.|MGX - Long-Term Debt|Company Short-Term Debt Metagenomi|Quick Liquidity metagenomi.co
- earnings and market ratios statistics:
MGX - Company Net Income
Initial company analysis:Metagenomi, Inc
Brand item of metagenomi.co

Metagenomi, Inc. (MGX) employs a robotic approach to genome editing that requires significant AI expenditures, leaving the company dependent on liquidity to fund scientist salaries during clinical trials. The short-term debt to equity trend reflects the ratio of current liabilities to shareholders' equity, allowing investors to assess default risk during corporate shocks or the aggressiveness of borrowing for expansion.

Competitors of Metagenomi, Inc. (MGX)

Short-Term Debt to Capital TEM|Short-Term Debt to Capital Qiagen Corp (QGEN)|Short-Term Debt to Equity Ionis Pharmaceuticals IONS|RGEN - Short-Term Debt to Equity Ratio|Avidity Biosciences, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital CRISPR Therapeutics Inc|WGS (Sema4) - Short-Term Debt to Equity Ratio|RARE: Short-Term Loans to Capital Ratio|BEAM (Beam Therapeutics Inc.) - Short-Term Debt to Capital|Short-Term Debt to Capital sarepta.com|Short-Term Debt to Capital TWST|10x Genomics Inc (TXG) - Short-Term Indebtedness to Equity|Short-Term Debt to Capital NTLA (Intellia)|Stoke Corp (STOK) - Current Liabilities to Capital|BLFS - Short-Term Debt to Equity|WVE (wavelifesciences.com) - Short-Term Debt to Capital Ratio|Maze Therapeutics (MAZE) - Short-Term Debt to Equity|Current Liabilities to Capital Sionna Therapeutics, Inc. (SION)|Short-Term Debt to Equity Prime Medicine Corp|Short-Term Debt to Equity Ratio Taysha Corp (TSHA)|Short-Term Debt to Capital QURE|Short-Term Debt to Capital Coefficient meiragtx.com|REGENXBIO - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital SLDB|Ocugen Corp - Short-Term Debt to Capital|Short-Term Debt to Capital Coefficient PacBio Corp PACB|Benitec Biopharma Inc. (BNTC) - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio DSGN|RCKT (Rocket Pharmaceuticals, Inc.) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio 4DMT (FDMT)|Short-Term Debt to Equity Ratio LXEO (Lexeo Therapeutics)|Short-Term Debt to Capital Coefficient korrobio.com|Short-Term Debt to Equity Editas Medicine, Inc. EDIT|SLN - Short-Term Debt to Equity Ratio|ProQR Therapeutics NV - Short-Term Debt to Capital|Short-Term Indebtedness to Equity Codexis, Inc. (CDXS)|SGMO (Sangamo) - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Ratio NAUT|DTIL (Precision BioSciences) - Short-Term Debt to Capital|Short-Term Debt to Capital Ratio GBIO (Generation Bio Corp)|Short-Term Debt to Equity Boundless Bio (BOLD)|exicuretx.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital IMNN (Imunon)|Short-Term Debt to Capital Phio Pharmaceuticals Corp PHIO|MBIO - Short-Term Debt to Equity|TransCode Therapeutics (RNAZ) - Short-Term Debt to Equity Ratio|BNGO: Short-Term Debt to Capital|Current Liabilities to Capital Applied DNA Sciences Inc (APDN)|Short-Term Debt to Equity Ratio BLUE|IPA (ImmunoPrecise) - Short-Term Loans to Capital Ratio|Short-Term Debt to Capital OMGA|Short-Term Debt to Capital singulargenomics.com (OMIC)|Short-Term Debt to Capital RGLS (Regulus Therapeutics Inc.)|Short-Term Indebtedness to Equity Syros Pharmaceuticals Inc.|Codex DNA - Short-Term Debt to Capital|Current Liabilities to Capital TRACON Pharmaceuticals, Inc|Unity Biotechnology (UBX) - Short-Term Debt to Equity